|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Gut-liver axis and probiotics: Their role in non-alcoholic fatty liver disease显示文摘The incidence of obesity and its related conditions, including non-alcoholic fatty liver disease(NAFLD), has dramatically increased in all age groups worldwide. Given the health consequences of these conditions, and the subsequent economic burden on healthcare systems, their prevention and treatment have become major priorities. Because standard dietary and lifestyle changes and pathogenically-oriented therapies(e.g., antioxidants, oral hypoglycemic agents, and lipid-lowering agents) often fail due to poor compliance and/or lack of efficacy, novel approaches directed toward other pathomechanisms are needed. Here we present several lines of evidence indicating that, by increasing energy extraction in some dysbiosis conditions or small intestinal bacterial overgrowth,specific gut microbiota and/or a'low bacterial richness'may play a role in obesity,metabolic syndrome,and fatty liver.Under conditions involving a damaged intestinal barrier('leaky gut'),the gut-liver axis may enhance the natural interactions between intestinal bacteria/bacterial products and hepatic receptors(e.g.,toll-like receptors),thus promoting the following cascade of events:oxidative stress,insulinresistance,hepatic inflammation,and fibrosis.We also discuss the possible modulation of gut microbiota by probiotics,as attempted in NAFLD animal model studies and in several pilot pediatric and adult human studies.Globally,this approach appears to be a promising and innovative add-on therapeutic tool for NAFLD in the context of multi-target therapy. | Giulia Paolella Claudia Mandato Luca Pierri Marco Poeta Martina Di Stasi Pietro Vajro | 2014 | World Journal of Gastroenterology2014，20，42： | 55 |
| 2 | Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions显示文摘Non-alcoholic fatty liver disease(NAFLD) in children is becoming a major health concern. A 'multiple-hit' pathogenetic model has been suggested to explain the progressive liver damage that occurs among children with NAFLD. In addition to the accumulation of fat in the liver, insulin resistance(IR) and oxidative stress due to genetic/epigenetic background, unfavorable lifestyles, gut microbiota and gut-liver axis dysfunction, and perturbations of trace element homeostasis have been shown to be critical for disease progression and the development of more severe inflammatory and fibrotic stages [non-alcoholic steatohepatitis(NASH)]. Simple clinical and laboratory parameters, such as age, history, anthropometrical data(BMI and waist circumference percentiles), blood pressure, surrogate clinical markers of IR(acanthosis nigricans), abdominal ultrasounds, and serum transaminases, lipids and glucose/insulin profiles, allow a clinician to identify children with obesity and obesity-related conditions, including NAFLD and cardiovascular and metabolic risks. A liver biopsy(the 'imperfect' gold standard) is required for a definitive NAFLD/NASH diagnosis, particularly to exclude other treatable conditions or when advanced liver disease is expected on clinical and laboratory grounds and preferably prior to any controlled trial of pharmacological/surgical treatments. However, a biopsy clearly cannot represent a screening procedure. Advancements in diagnostic serum and imaging tools, especially for the non-invasive differentiation between NAFLD and NASH, have shown promising results, e.g., magnetic resonance elastography. Weight loss and physical activity should be the first option of intervention.Effective pharmacological treatments are still under development; however, drugs targeting IR, oxidative stress, proinflammatory pathways, dyslipidemia, gut microbiota and gut liver axis dysfunction are an option for patients who are unable to comply with the recommended lifestyle changes. When morbid obesity prevails, bariatric surgery should be considered. | Maria Grazia Clemente Claudia Mandato Marco Poeta Pietro Vajro | 2016 | World Journal of Gastroenterology2016，22，36： | 32 |
| 3 | DNA end binding activity and Ku70/80 heterodimer expression in human colorectal tumor显示文摘AIM: To determine the DNA binding activity and protein levels of the Ku70/80 heterodimer, the functional mediator of the NHEJ activity, in human colorectal carcinogenesis.METHODS: The Ku70/80 DNA-binding activity was determined by electrophoretic mobility shift assays in 20 colon adenoma and 15 colorectal cancer samples as well as matched normal colonic tissues. Nuclear and cytoplasmic protein expression was determined by immunohistochemistry and Western blot analysis.RESULTS: A statistically significant difference was found in both adenomas and carcinomas as compared to matched normal colonic mucosa (P<0.00). However,changes in binding activity were not homogenous with approximately 50% of the tumors showing a clear increase in the binding activity, 30% displaying a modest increase and 15% showing a decrease of the activity.Tumors, with increased DNA-binding activity, also showed a statistically significant increase in Ku70 and Ku86nuclear expression, as determined by Western blot and immunohistochemical analyses (P<0.001). Cytoplasmic protein expression was found in pathological samples,but not in normal tissues either from tumor patients or from healthy subjects.CONCLUSION: Overall, our DNA-binding activity and protein level are consistent with a substantial activation of the NHEJ pathway in colorectal tumors. Since the NHEJ is an error prone mechanism, its abnormal activation can result in chromosomal instability and ultimately lead to tumorigenesis. | Paola Mazzarelli Paola Parrella Davide Seripa Emanuela Signori Giuseppe Perrone Carla Rabitti Domenico Borzomati Armando Gabbrielli Maria Giovanna Matera Carolina Gravina Marco Caricato Maria Luana Poeta Monica Rinaldi Sergio Valeri Roberto Coppola Vito Michele Fazio | 2005 | World Journal of Gastroenterology2005，11，42： | 4 |
| 4 | Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab 显示文摘 | Stasi R Cooper N Del Poeta G | 2008 | Blood2008，112，4： | 1 |
| 5 | First report of CTX-M producing Escherichia coli , including the new ST2526, isolated from beef cattle and sheep in Portugal显示文摘 | Sónia Ramos Gilberto Igrejas Nuno Silva Daniela Jones-Dias José-Luís Capelo-Martinez Manuela Cani?a Patrícia Poeta | 2013 | Food Control2013，，1： | 1 |
| 6 | Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells 显示文摘 | Del Poeta M Chen SF Von Hoff D | 1999 | Antimicrob Agents Chemother1999，43，12： | 1 |
| 7 | CD7 expression in acute myeloid leukemia显示文摘 | Del Poeta G Stasi R Venditti A | 1995 | Leuk Lymphoma1995，17，12： | 1 |
| 8 | TP53 mutations and survival in squamous-cell carcinoma of the head and neck显示文摘 | Poeta ML Manola J Goldwasser MA | 2007 | N Engl J Med2007，357，25： | 1 |
| 9 | Prognostic value of cell mark er analysis in de novo acute myeloid leukemia显示文摘 | Stasi R Vendrrn A | 1994 | Leukemia1994，8，： | 1 |
| 10 | The Ligamp TP53 Assay for Detection of Minimal Residual Disease in Head and Neck Squamous Cell Carcinoma Surgical Margins显示文摘 | Poeta ML Manola J Goldenberg D | 2009 | Clin Cancer Res2009，15，24： | 1 |
| 11 | Seagulls of the Berlengas natural reserve of Portugal as carriers of fecal Escherichia coli harboring CTX-M and TEM extended-spectrum beta-lactamases显示文摘 | Poeta P Radhouani H Igrejas G | 2008 | Appl Environ Microbiol2008，74，23： | 1 |
| 12 | Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B celldepleting therapy with rituximab显示文摘 | Stasi R Cooper N Del Poeta G | 2008 | Blood2008，112，4： | 1 |
| 13 | Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia显示文摘 | Buccisano F Del Poeta G | 2000 | Blood2000，96，12： | 1 |
| 14 | CD7 expression in acute myeloid leukemia显示文摘 | Poeta GD Stasi R Venditti A | 1993 | Blood1993，82，： | 1 |
| 15 | Detection of Escherichia coli harbouring extended-spectrum beta-lactamases of the CTX-M, TEM and SHV classes in faecal samples of wild animals in Portu- gal显示文摘 | Costa D Poeta P Saenz Y | 2006 | J Antimicrob Chemother2006，58，6： | 1 |
| 16 | Response to B-cell de- pleting therapy with rituximab reverts the abnormalities of T- cell subsets in patients with idiopathic thrombocytopenic pur- pura显示文摘 | Stasi R Del Poeta G Stipa E | 2007 | Blood2007，110，8： | 1 |
| 17 | Response to B-cell-depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura 显示文摘 | Stasi R Del Poeta G Stipa E | 2007 | Blood2007，110，8： | 1 |
| 18 | Virulence factors and bac teriocins in faecal enterococci of wild boars显示文摘 | Poeta P Igrejas G Costa D | 2008 | J Basic Microbi- ol2008，485，： | 1 |
| 19 | Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell depleting therapy with rituximab显示文摘 | Stasi R Cooper N del Poeta G | 2008 | Blood2008，112，4： | 1 |
| 20 | Level of minimal residual disease after consolidation therapy pre- dicts outcome in acute myeloid leukemia 显示文摘 | Venditti A Buccisano F Del Poeta G | 2000 | Blood2000，96，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员